NO20060428L - 2-amino-bicyklo[3.1.0]heksan-2,6-dikarboksylesterderivat - Google Patents
2-amino-bicyklo[3.1.0]heksan-2,6-dikarboksylesterderivatInfo
- Publication number
- NO20060428L NO20060428L NO20060428A NO20060428A NO20060428L NO 20060428 L NO20060428 L NO 20060428L NO 20060428 A NO20060428 A NO 20060428A NO 20060428 A NO20060428 A NO 20060428A NO 20060428 L NO20060428 L NO 20060428L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen atom
- hexane
- alkyl group
- different
- dikarboksylesterderivat
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 1
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- -1 hexane-2,6-dicarboxylic acid ester Chemical class 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
Abstract
Legemiddel effektivt for behandling og hindring av psykiatriske forstyrrelser slike som schizofreni, angst og relaterte lidelser derav, depresjon, bipolar forstyrrelse og epilepsi. Legemiddelet antagoniserer virkningen til gruppe II metabotrofiske glutamatreseptorer og viser høyaffinitet ved oral administrasjon. 2-Aminobisyklo[3.I.0]heksan-2,6-dikarboksylsyre-esterderivatet representert ved formel [I] hvori R1 og R2 er identiske eller forskjellige og hver representerer et hydrogenatom, en C1-10 alkylgruppe eller lignende; X representerer et hydrogenatom eller et fluoratom; Y representerer OCHR3R4 eller lignende (hvori R3 og R4 er identiske eller forskjellige, og hver representerer et hydrogenatom, en C1-10 alkylgruppe eller lignende; og n representerer heltallet 1 eller 2), et farmasøytisk akseptabelt salt derav eller et hydrat derav.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003181930 | 2003-06-26 | ||
JP2003373511 | 2003-10-31 | ||
JP2004128663 | 2004-04-23 | ||
PCT/JP2004/009398 WO2005000791A1 (ja) | 2003-06-26 | 2004-06-25 | 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20060428L true NO20060428L (no) | 2006-03-10 |
NO335004B1 NO335004B1 (no) | 2014-08-25 |
Family
ID=33556154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060428A NO335004B1 (no) | 2003-06-26 | 2006-01-26 | 2-Aminobicyklo[3.1.0]heksan-2,6-dikarboksylsyre-esterderivat |
Country Status (21)
Country | Link |
---|---|
US (5) | US7960579B2 (no) |
EP (3) | EP2287147B1 (no) |
JP (1) | JP4792971B2 (no) |
KR (1) | KR101071507B1 (no) |
AT (1) | ATE487690T1 (no) |
AU (2) | AU2004252017B2 (no) |
BR (1) | BRPI0411823A (no) |
CA (1) | CA2530706C (no) |
CY (1) | CY1110997T1 (no) |
DE (1) | DE602004030007D1 (no) |
DK (2) | DK2123630T3 (no) |
ES (1) | ES2394175T3 (no) |
HK (1) | HK1095318A1 (no) |
HR (1) | HRP20100619T1 (no) |
MX (1) | MXPA05013740A (no) |
NO (1) | NO335004B1 (no) |
NZ (2) | NZ544131A (no) |
PL (1) | PL1637517T3 (no) |
PT (1) | PT1637517E (no) |
SI (1) | SI1637517T1 (no) |
WO (1) | WO2005000791A1 (no) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1637517T3 (pl) * | 2003-06-26 | 2011-04-29 | Taisho Pharmaceutical Co Ltd | Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego |
TW201129700A (en) | 2009-11-18 | 2011-09-01 | Taisho Pharmaceutical Co Ltd | Method for producing optically active bicyclo [310] hexane derivative using oxygen |
WO2011061935A1 (ja) * | 2009-11-19 | 2011-05-26 | 大正製薬株式会社 | 3-アルコキシ-2-アミノ-6-フルオロビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体及びその中間体の製造方法 |
ES2682959T3 (es) * | 2010-11-18 | 2018-09-24 | Eli Lilly And Company | Compuestos de 3-benciloxi-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGLuR 2/3 |
TWI520935B (zh) | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
JP5983713B2 (ja) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | 含フッ素アミノ酸のプロドラッグを含有する医薬 |
FR3026843B1 (fr) * | 2014-10-03 | 2016-11-18 | Univ Pierre Et Marie Curie (Paris 6) | Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture |
PL3445743T3 (pl) | 2016-04-18 | 2021-12-20 | Taisho Pharmaceutical Co., Ltd. | Prolek pochodnej aminokwasów |
CN110191709A (zh) | 2017-01-17 | 2019-08-30 | 德州大学系统董事会 | 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物 |
KR101877672B1 (ko) | 2017-04-03 | 2018-07-11 | 엘에스산전 주식회사 | Ad컨버터 |
EP3823604A4 (en) * | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | COMPOUNDS USEFUL AS INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE INHIBITORS |
US11501618B1 (en) * | 2018-10-19 | 2022-11-15 | Amazon Technologies, Inc. | Security device with user-configurable motion detection settings |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | 6−フルオロビシクロ[3.1.0]ヘキサン誘導体 |
DK1110943T3 (da) | 1998-08-31 | 2004-10-11 | Taisho Pharmaceutical Co Ltd | 6-fluorbicyclo[3.1.0]hexanderivater |
CH694053A5 (de) | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
EP1295865A4 (en) | 2000-06-28 | 2005-06-01 | Taisho Pharmaceutical Co Ltd | NEW DICARBOXYLENE DERIVATIVES |
EP1370519A1 (en) | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetic excitatory amino acids |
WO2003061698A1 (fr) * | 2001-12-27 | 2003-07-31 | Taisho Pharmaceutical Co.,Ltd. | Derives de 6-fluorobicyclo[3.1.0]hexane |
WO2005000790A1 (ja) | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体 |
PL1637517T3 (pl) * | 2003-06-26 | 2011-04-29 | Taisho Pharmaceutical Co Ltd | Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego |
JP2007063129A (ja) | 2003-06-26 | 2007-03-15 | Taisho Pharmaceut Co Ltd | 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体 |
-
2004
- 2004-06-25 PL PL04746867T patent/PL1637517T3/pl unknown
- 2004-06-25 KR KR1020057024818A patent/KR101071507B1/ko not_active IP Right Cessation
- 2004-06-25 US US10/562,018 patent/US7960579B2/en not_active Expired - Fee Related
- 2004-06-25 MX MXPA05013740A patent/MXPA05013740A/es active IP Right Grant
- 2004-06-25 DK DK09166100.9T patent/DK2123630T3/da active
- 2004-06-25 NZ NZ544131A patent/NZ544131A/xx not_active IP Right Cessation
- 2004-06-25 BR BRPI0411823-5A patent/BRPI0411823A/pt not_active IP Right Cessation
- 2004-06-25 DE DE602004030007T patent/DE602004030007D1/de not_active Expired - Lifetime
- 2004-06-25 EP EP10181930.8A patent/EP2287147B1/en not_active Expired - Lifetime
- 2004-06-25 JP JP2005511127A patent/JP4792971B2/ja not_active Expired - Lifetime
- 2004-06-25 CA CA2530706A patent/CA2530706C/en not_active Expired - Fee Related
- 2004-06-25 EP EP04746867A patent/EP1637517B1/en not_active Expired - Lifetime
- 2004-06-25 SI SI200431569T patent/SI1637517T1/sl unknown
- 2004-06-25 PT PT04746867T patent/PT1637517E/pt unknown
- 2004-06-25 ES ES09166100T patent/ES2394175T3/es not_active Expired - Lifetime
- 2004-06-25 WO PCT/JP2004/009398 patent/WO2005000791A1/ja active Application Filing
- 2004-06-25 NZ NZ580554A patent/NZ580554A/en not_active IP Right Cessation
- 2004-06-25 DK DK04746867.3T patent/DK1637517T3/da active
- 2004-06-25 AU AU2004252017A patent/AU2004252017B2/en not_active Ceased
- 2004-06-25 AT AT04746867T patent/ATE487690T1/de active
- 2004-06-25 EP EP09166100A patent/EP2123630B1/en not_active Expired - Lifetime
-
2006
- 2006-01-26 NO NO20060428A patent/NO335004B1/no not_active IP Right Cessation
-
2007
- 2007-01-25 HK HK07100898.6A patent/HK1095318A1/xx not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,482 patent/US8039647B2/en not_active Expired - Fee Related
- 2009-09-15 AU AU2009217374A patent/AU2009217374B2/en not_active Ceased
-
2010
- 2010-07-30 US US12/847,392 patent/US8076502B2/en not_active Expired - Fee Related
- 2010-11-15 HR HR20100619T patent/HRP20100619T1/hr unknown
- 2010-12-17 CY CY20101101160T patent/CY1110997T1/el unknown
-
2011
- 2011-09-08 US US13/227,942 patent/US8350060B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,242 patent/US8258133B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060428L (no) | 2-amino-bicyklo[3.1.0]heksan-2,6-dikarboksylesterderivat | |
NO20071660L (no) | Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer | |
DE50307267D1 (de) | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
RS51280B (sr) | Novi derivati hidantoina za tretman obstruktivnih bolesti dišnih puteva | |
NO20060774L (no) | Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer | |
RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
YU45403A (sh) | Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida | |
DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
NO20052730L (no) | Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser | |
CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
RU2001116117A (ru) | Новые пиперазиновые и пиперидиновые соединения | |
DK0808303T3 (da) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister | |
ATE247645T1 (de) | Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung | |
PL2155736T3 (pl) | Nowy związek, karbamoiloksyaryloalkanoiloarylopiperazyna, kompozycje farmaceutyczne zawierające ten związek oraz sposoby leczenia bólu, stanu lękowego i depresji przez podawanie tego związku | |
WO1999021848A3 (en) | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands | |
SG146627A1 (en) | Imidazole derivatives | |
SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
BRPI0510564A (pt) | compostos e tautÈmeros, estereoisÈmeros, e sais farmacologicamente aceitáveis dos mesmos, composições farmacêuticas, método para preparar composições farmacêuticas, e, uso de um composto | |
DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
HUP0201720A2 (hu) | Szorongás és depresszió kezelésére szolgáló kombinált készítmények és alkalmazásuk | |
HK1075656A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
HUP0100540A2 (hu) | Szubsztituált oximok mint neurokinin antagonisták | |
WO2007136302A3 (fr) | Substances actives, composition pharmaceutique et procédé de fabrication et d'utilisations correspondants | |
RS50275B (sr) | Derivati caloporosida, postupak za njihovu proizvodnju i njihova primena |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |